Abstract
Monoclonal antibodies that target CD20 and CD52 have been evaluated in the setting of chronic lymphocytic leukemia over the past 2 decades. Incorporating these agents into chemotherapy regimens has improved disease control, making chemoimmunotherapy standard first-line treatment. Further understanding of these agents is imperative for providing good medical care by the advanced practitioner. This review will focus on the development of monoclonal antibodies, as well as describe the efficacy and safety data, administration recommendations, and select safety and monitoring parameters for rituximab, ofatumumab, obinutuzumab, and alemtuzumab.
